Article Text

Download PDFPDF
Lipid lowering in primary prevention: time to focus on young patients

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors Dr GMG contributed to the planning and conduct of the article Dr AH contributed to the bibliography and writing of the article.

  • Funding Dr. GMG is supported by the Fonds de la Recherche du Québec - Santé (Junior 1 Clinical Research Scholar).

  • Competing interests Dr. GMG reports speaker/advisory board fees from Novartis, Bayer, Canadian Association of Interventional Cardiology, KYE, CSI, Boston Scientific, Pharmascience and JAMP Pharma; and research funds from the Fonds de Recherche du Québec - Santé, Canadian Institutes of Health Research, Bayer and Boston Scientific. None are related to the current manuscript.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles